Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. METHODS: We randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them for a median of 2.1 years. Physicians were permitted to adjust other medications, including antihyperglycemic agents. The primary end point was a composite of cardiovascular death, myocardial infarction, or ischemic stroke. RESULTS: A primary end-point event occurred in 613 patients in the saxagliptin group and in 609 patients in the placebo group (7.3% and 7.2%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio with saxagliptin, 1.00; 95% confidence interval [CI], 0.89 to 1.12; P=0.99 for superiority; P<0.001 for noninferiority); the results were similar in the "on-treatment" analysis (hazard ratio, 1.03; 95% CI, 0.91 to 1.17). The major secondary end point of a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or heart failure occurred in 1059 patients in the saxagliptin group and in 1034 patients in the placebo group (12.8% and 12.4%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio, 1.02; 95% CI, 0.94 to 1.11; P=0.66). More patients in the saxagliptin group than in the placebo group were hospitalized for heart failure (3.5% vs. 2.8%; hazard ratio, 1.27; 95% CI, 1.07 to 1.51; P=0.007). Rates of adjudicated cases of acute and chronic pancreatitis were similar in the two groups (acute pancreatitis, 0.3% in the saxagliptin group and 0.2% in the placebo group; chronic pancreatitis, <0.1% and 0.1% in the two groups, respectively). CONCLUSIONS: DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes. (Funded by AstraZeneca and Bristol-Myers Squibb; SAVOR-TIMI 53 ClinicalTrials.gov number, NCT01107886.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Trials of HF outcomes with dapagliflozin and empagliflozin, enrolling up to 50% of participants with type 2 diabetes, report reduction in cardiovascular death and improvement of HF among patients with HF with reduced ejection fraction and HF with preserved ejection fraction, respectively, independent of diabetes status, compared with placebo.66–69,88”
From Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review (2025) · cites this paper as [69]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 4 trials to date, the DPP4 inhibitors have been shown to be neutral in terms of cardiovascular outcomes.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [186]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of SAVOR-TIMI 53 (NCT01107886) and EXAMINE (NCT00968708) were recently released and showed no increased risk of cardiovascular events with the DPP-4 inhibitors saxagliptin96 and alogliptin97, respectively.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [19]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Self-citationThe Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Cited by
Items 701–800 of 1,020
Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?
Ahmad, E., Sargeant, J. A., Zaccardi, F., Khunti, K., Webb, D. R., & Davies, M. J. (2020) · Pharmaceuticals · doi:10.3390/ph13120427 · Cited by 61
“007) [86], albeit not a primary outcome of the study.”
BackgroundEarly therapy for type 2 diabetes in China
Yang, W., & Weng, J. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70136-6 · Cited by 57
McGovern, A. P., Hinton, W., Correa, A., Munro, N. M., Whyte, M., & de Lusignan, S. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012801 · Cited by 55
Trajectories of fasting plasma glucose variability and mortality in type 2 diabetes
Lee, C.-L., Sheu, W. H., Lee, I., Lin, S., Liang, W., Wang, J., & Li, Y. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.09.001 · Cited by 54
Incretin-Based Drugs and the Risk of Congestive Heart Failure
Yu, O. H. Y., Filion, K. B., Azoulay, L., Patenaude, V., Majdan, A., & Suissa, S. (2015) · Diabetes Care · doi:10.2337/dc14-1459 · Cited by 53
Updates on cardiovascular outcome trials in diabetes
on behalf of the D&CVD EASD Study Group, Schnell, O., Rydén, L., Standl, E., & Ceriello, A. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0610-y · Cited by 52
“SAVIOR-TIMI53 and EXAMINE however indicated an increase in risk of hospitalization for HF [12, 13].”
BackgroundHeart failure and type 2 diabetes: From cardiovascular outcome trials, with hope
Giugliano, D., Meier, J. J., & Esposito, K. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13629 · Cited by 52
Faber, R., Zander, M., Pena, A., Michelsen, M. M., Mygind, N. D., & Prescott, E. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0206-3 · Cited by 51
“(enzyme responsible for the degradation of GLP-1) on the cardiovascular system came out neutral [31,32].”
BackgroundGunton, J. E., Cheung, N. W., Davis, T. M. E., Zoungas, S., & Colagiuri, S. (2014) · Medical Journal of Australia · doi:10.5694/mja14.01187 · Cited by 51
“One large randomised controlled trial (RCT) reported no change in overall cardiovascular safety but increased hospital admissions for heart failure amongst patients with or at risk of cardiovascular events (11).”
BackgroundNyström, T., Bodegård, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.12.004 · Cited by 58
Chan, C.-W., Yu, C.-L., Lin, J.-C., Hsieh, Y.-C., Lin, C.-C., Hung, C.-Y., Li, C.-H., Liao, Y.-C., Lo, C.-P., Huang, J.-L., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0663-6 · Cited by 51
Challenges of Non–Intention-to-Treat Analyses
DeMets, D. L., & Cook, T. D. (2018) · JAMA · doi:10.1001/jama.2018.19192 · Cited by 52
Do Current Clinical Trials Meet Society’s Needs?
Pocock, S., & Gersh, B. J. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.08.008 · Cited by 54
Acute kidney injury in diabetes mellitus: Epidemiology, diagnostic, and therapeutic concepts
Gui, Y., Palanza, Z., Fu, H., & Zhou, D. F. (2023) · The FASEB Journal · doi:10.1096/fj.202201340rr · Cited by 61
Yao, M., Hao, Y., Wang, T., Xie, M., Li, H., Feng, J., Feng, L., & Ma, D. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1149671 · Cited by 56
Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis
Hanlon, P., Butterly, E. W., Wei, L. S., Wightman, H., Almazam, S. A., Alsallumi, K., Crowther, J., McChrystal, R., Rennison, H., Hughes, K., et al. (2025) · JAMA · doi:10.1001/jama.2024.27402 · Cited by 64
Liu, Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.9090 · Cited by 49
Vasopressin, from Regulator to Disease Predictor for Diabetes and Cardiometabolic Risk
Melander, O. (2016) · Annals of Nutrition and Metabolism · doi:10.1159/000446201 · Cited by 60
Hiromura, M., Mori, Y., Kohashi, K., Terasaki, M., Shinmura, K., Negoro, T., Kawashima, H., Kogure, M., Wachi, T., Watanabe, R., et al. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0152 · Cited by 52
“Then, the cells were incubated in phosphate-buffered saline (PBS) containing 10 nmol/L of an adenyl cyclase activator, folskolin (positive control; SigmaAldrich), 10 nmol/L of GLP-1 (human GLP-1(7–36); AnaSpec), or 1 or 10 nmol/L of GIP (human GIP(1-42); AnaSpec) at 37°C for 20 min.”
MethodShould Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
Grunberger, G. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0853-8 · Cited by 54
Mechanisms linking empagliflozin to cardiovascular and renal protection
Filardi, P. P., Avogaro, A., Bonora, E., Colivicchi, F., Fioretto, P., Maggioni, A. P., Sesti, G., & Ferrannini, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.089 · Cited by 56
Kim, Y., Han, S. J., Kim, D. J., Lee, K. W., & Kim, H. J. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0737-5 · Cited by 53
“Saxagliptin has been reported to be associate with HF, which has caused global controversy [4, 5].”
Background2020 vision – An overview of prospects for diabetes management and prevention in the next decade
Wang, C., Neil, D. L., & Home, P. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.007 · Cited by 57
The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus
Hussain, S. T., & Chowdhury, T. A. (2019) · Drugs · doi:10.1007/s40265-019-1061-4 · Cited by 58
The kidney and cardiovascular outcome trials: 肾脏与心血管结局试验
Bloomgarden, Z. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12616 · Cited by 51
“Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)–Thrombolysis in Myocardial Infarction (TIMI) 53 trial, saxagliptin was associated with significantly less worsening and more improvement in microalbumin levels at 1 year, at 2 years, and by endof-treatment.(11) The reduction in microalbumin levels”
MethodTseng, C. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011640 · Cited by 51
Cahn, A., Wiviott, S. D., Mosenzon, O., Murphy, S. A., Goodrich, E. L., Yanuv, I., Rozenberg, A., Wilding, J. P. H., Leiter, L. A., Bhatt, D. L., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14179 · Cited by 51
“Most DPP-4 inhibitors are neutral with respect to HHF, although a significant increased risk has been observed with saxagliptin.(3) GLP-1 RAs have been shown to have a modest benefit on reducing HHF,”
BackgroundSelf-citationUssher, J. R., Greenwell, A. A., Nguyen, M.-A., & Mulvihill, E. E. (2022) · Diabetes · doi:10.2337/dbi20-0049 · Cited by 50
Yandrapalli, S., Jolly, G., Horblitt, A., Sanaani, A., & Aronow, W. S. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1358064 · Cited by 50
Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus
Connelly, K. A., Yan, A. T.-K., Leiter, L. A., Bhatt, D. L., & Verma, S. (2015) · Circulation · doi:10.1161/circulationaha.115.015946 · Cited by 54
Self-citationRomacho, T., Vallejo, S., Villalobos, L. A., Wronkowitz, N., Indrakusuma, I., Sell, H., Eckel, J., Sánchez‐Ferrer, C. F., & Peiró, C. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000886 · Cited by 51
Mordi, N., Mordi, I. R., Singh, J. S., Baig, F., Choy, A. M., McCrimmon, R. J., Struthers, A. D., & Lang, C. C. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-018097 · Cited by 52
Rørth, R., Jhund, P. S., Mogensen, U. M., Kristensen, S. L., Petrie, M. C., Køber, L., & McMurray, J. J. V. (2018) · Diabetes Care · doi:10.2337/dc17-2583 · Cited by 53
Mansour, A. A., Alibrahim, N. T. Y., Alidrisi, H. A., Alhamza, A. H. A., Almomin, A., Zaboon, I. A., Kadhim, M. B., Hussein, R. N., Nwayyir, H. A., Mohammed, A. G., et al. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.03.008 · Cited by 64
Scheen, A. J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.12.005 · Cited by 51
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
“In the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)–Thrombolysis in Myocardial Infarction (TIMI) 53 trial (SAVOR–TIMI53) [117], 16,492 patients with type 2 diabetes mellitus were enrolled (saxagliptin group 8280, placebo 8212).”
BackgroundMethodResultInfluentialBertoccini, L., & Baroni, M. G. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_494 · Cited by 49
Chen, D., Wang, S.-H., Mao, C., Tsai, M., Lin, Y., Chou, C., Wen, M., Wang, C., Hsieh, C., Hung, K., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.12.029 · Cited by 49
“Conversely, the SAVOR trial found saxagliptin did not affect the rate of ischemic events, though the rate of hospitalization for heart failure was increased (26).”
BackgroundPharmacologic Management of Type 2 Diabetes: 2016 Interim Update
(2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.02.006 · Cited by 53
DPP4 as a Potential Candidate in Cardiovascular Disease
Chen, S.-Y., Kong, X.-Q., Zhang, K.-F., Luo, S., Wang, F., & Zhang, J. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s380285 · Cited by 56
“The risk of MACE was similar in patients in the DPP4 inhibitor and placebo group, demonstrating the cardiovascular safety of alogliptin and saxagliptin.(5,6) Similarly, the”
ResultTreatment of type 2 diabetes patients with heart conditions
Aktaş, G., Tel, B. M. A., Tel, M. R., & Balci, B. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204941 · Cited by 51
“Similarly, there was no association between DPP-4 inhibitors and incident AF in diabetic patients in large clinical trials, including Examine, Carmelina, and Savor-Timi studies [18,19,73].”
BackgroundAntidiabetic Agents and Endothelial Dysfunction – Beyond Glucose Control
Eriksson, L., & Nyström, T. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12402 · Cited by 52
Davis, T. M. E. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12295 · Cited by 50
“In SAVOR TIMI 53, people were excluded if they had ESRD and were undergoing long-term dialysis, had undergone a renal transplantation or had a serum creatinine >530 μmol/l [4].”
BackgroundResultInfluentialValidation of the UKPDS 82 risk equations within the Cardiff Diabetes Model
McEwan, P., Ward, T., Bennett, H., & Bergenheim, K. (2015) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-015-0038-8 · Cited by 50
“The specific external validation studies included in this analysis were: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) [20]; the Veterans Affairs Diabetes Trial (VADT) [21]; the Action in Diabetes and Vascular Disease: Preterax and Diamicro…”
MethodCD26 and Asthma: a Comprehensive Review
Nieto‐Fontarigo, J. J., González‐Barcala, F. J., José, E. S., Arias, P., Nogueira, M., & Salgado, F. J. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8578-z · Cited by 55
Mannucci, E., & Monami, M. (2017) · Advances in Therapy · doi:10.1007/s12325-016-0432-4 · Cited by 49
“Randomized Controlled Trial Data We identified one primary article and one secondary article for the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial [28, 45], one primary article and two secondary articles for the Saxagliptin Assessment of Vascular Outcomes Recorded in Pa…”
BackgroundMethodResultInfluentialTakebayashi, K., & Inukai, T. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3112w · Cited by 53
Wu, S., Chai, S., Yang, J., Cai, T., Xu, Y., Yang, Z., Zhang, Y., Ji, L., Sun, F., & Zhan, S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.07.036 · Cited by 53
Antidiabetic drugs and stroke risk. Current evidence
Castilla‐Guerra, L., Fernández‐Moreno, M. D. C., Jiménez, D. L., & Nimo, E. C. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.09.019 · Cited by 55
“The three completed large prospective CV outcome trials of the DPP-4 inhibitors saxagliptin, alogliptin, and sitagliptin generally indicate a neutral effect on CVevents and stroke [5,26,27,28].”
BackgroundMethodCombination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
Moon, M. K., Hur, K. Y., Ko, S., Park, S.-O., Lee, B., Kim, J. H., Rhee, S. Y., Kim, H. J., Choi, K. M., & Kim, N. H. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.5.357 · Cited by 54
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
Blonde, L., Dipp, S., & Cadena, D. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0694-0 · Cited by 56
“However, results for the risk of hospitalization for heart failure were conflicting, with a statistically significant increase in risk reported for saxagliptin [24, 25], a nonsignificant increase with alogliptin [23, 26], and no increase with sitagliptin [22, 27].”
BackgroundLee, H., Chen, S., Liu, J., Li, P., Wu, L., Chang, S., Yeh, Y., Kuo, C.-T., Chan, Y., & See, L. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01118-0 · Cited by 58
Lee, S., Zhou, J., Leung, K. S. K., Wai, A. K. C., Jeevaratnam, K., King, E., Liu, T., Wong, W. T., Chang, C., Wong, I. C. K., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07319-x · Cited by 53
DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
Razavi, M. A., Wei, Y., Rao, X., & Zhong, J. (2022) · Military Medical Research · doi:10.1186/s40779-022-00410-2 · Cited by 58
“CVOTs on DPP‐4i Data from TECOS, EXAMINE, SAVOR-TIMI53, CARMELINA, and CAROLINA showed that DPP-4i are noninferior to the placebo or glimepiride relative to primary cardiovascular endpoints [17, 48, 49, 57, 58].”
MethodJensen, T. M., Saha, K., & Steinberg, W. M. (2015) · Diabetes Care · doi:10.2337/dc13-1210 · Cited by 48
Thein, D., Christiansen, M. N., Mogensen, U. M., Bundgaard, J. S., Rørth, R., Madelaire, C., Fosbøl, E. L., Schou, M., Torp-Pedersen, C. T., Gislason, G., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01078-5 · Cited by 51
Mima, A., Nomura, A., & Fujii, T. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115032 · Cited by 49
First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus
Kaku, K. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1099630 · Cited by 50
Cairano, E. S. D., Moretti, S., Marciani, P., Sacchi, V. F., Castagna, M., Davalli, A. M., Folli, F. B., & Perego, C. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25176 · Cited by 52
“Through GLP1R activation, insulin secretion is augmented, while glucagon release is suppressed (Scrocchi et al., 1998).”
BackgroundScheen, A. J. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0157-y · Cited by 49
“Pooled analyses of large clinical trials with sitagliptin [34], vildagliptin [40] and linagliptin [48] (Table 2) as well as data from the two recently published major cardiovascular outcome studies reporting liver safety data with saxagliptin [45] and alogliptin [53] (Table 3) are reassuring.”
BackgroundResultInfluentialPharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients
Mendez, C. E., & Umpierrez, G. E. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.3.180 · Cited by 46
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
Terawaki, Y., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Takahashi, H., Tanaka, T., Murase, K., Nagaishi, R., Tanabe, M., & Yanase, T. (2014) · Cardiovascular Diabetology · doi:10.1186/preaccept-9752811371415510 · Cited by 51
DPP-4 inhibition has beneficial effects on the heart after myocardial infarction
Kubota, A., Takano, H., Wang, H., Hasegawa, H., Tadokoro, H., Hirose, M., Kobara, Y., Yamada-Inagawa, T., Komuro, I., & Kobayashi, Y. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.12.026 · Cited by 48
Esposito, K., Chiodini, P., Capuano, A., Maiorino, M. I., Bellastella, G., & Giugliano, D. (2013) · Endocrine · doi:10.1007/s12020-013-0090-0 · Cited by 54
Mannucci, E., Mosenzon, O., & Avogaro, A. (2016) · Diabetes Care · doi:10.2337/dcs15-3024 · Cited by 48
Self-citationLi, J., Zheng, J., Wang, S., Lau, H. K., Fathi, A., & Wang, Q. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00015 · Cited by 47
“Nevertheless, clinical studies specifically designed to evaluate the potential cardiovascular benefits of 9-36a in patients with T2DM are warranted.”
BackgroundDei, A., Spigoni, V., Cito, M., Aldigeri, R., Ridolfi, V., Marchesi, E., Marina, M., Derlindati, E., Aloe, R., Bonadonna, R. C., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0503-0 · Cited by 48
Hung, Y., Lin, C., Chen, H.-J., Chang, M. P., Huang, K. C., Chen, Y.-J., & Chen, C.-C. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4021-4 · Cited by 52
Schott, G., Martinez, Y. V., de Silva, R. E. E., Guiteras, A. R., Vögele, A., Reeves, D., Kunnamo, I., Marttila-Vaara, M., & Sönnichsen, A. C. (2017) · BMC Geriatrics · doi:10.1186/s12877-017-0571-8 · Cited by 52
“Saxagliptin Saxagliptin (5 mg/daily) was compared to placebo in one study reported by four publications with the following outcomes: a composite outcome of cardiovascular death, myocardial infarction, or ischemic stroke [41], hospitalisation for heart failure [12], a composite outcome of cardiovascular mortality, nonf…”
BackgroundTreatment of type 2 diabetes mellitus in elderly patients
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.12.004 · Cited by 54
Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes
Wang, X., Zheng, P., Huang, G., Yang, L., & Zhou, Z. (2018) · Clinical and Experimental Medicine · doi:10.1007/s10238-018-0519-0 · Cited by 51
Bonora, B. M., Cappellari, R., Albiero, M., Avogaro, A., & Fadini, G. P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00824 · Cited by 53
Phrommintikul, A., Wongcharoen, W., Kumfu, S., Jaiwongkam, T., Gunaparn, S., Chattipakorn, S. C., & Chattipakorn, N. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13903 · Cited by 54
The future of new drugs for diabetes management
Bailey, C. J., & Day, C. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107785 · Cited by 52
“Although DPP-4 inhibitors have not altered the rates of MI and stroke in the CVOTs, a possible association of somemembers of the class with more hospitalization for heart failure cannot be excluded [17,18].”
BackgroundLim, S., Oh, T. J., Dawson, J., & Sattar, N. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13850 · Cited by 45
Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
Wiciński, M., Górski, K. M., Wódkiewicz, E., Walczak, M., Nowaczewska, M., & Malinowski, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072275 · Cited by 53
The cardiovascular safety of incretin-based therapies: a review of the evidence
Petrie, J. R. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-130 · Cited by 45
Diabetes mellitus and atrial fibrillation-from pathophysiology to treatment
Leopoulou, M., Theofilis, P., Kordalis, A., Παπαγεωργίου, Ν., Sagris, Μ., Oikonomou, E. K., & Tousoulis, D. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i5.512 · Cited by 53
Marston, N., Pirruccello, J. P., Melloni, G. E. M., Kamanu, F., Bonaca, M. P., Giugliano, R. P., Scirica, B. M., Wiviott, S. D., Bhatt, D. L., Steg, P. G., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03188-z · Cited by 51
Self-citationAn overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 44
“trial [113] or with alogliptin in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)”
MethodEkström, N., Svensson, A., Miftaraj, M., Franzén, S., Zethelius, B., Eliasson, B., & Gudbjörnsdottir, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12704 · Cited by 46
“Missing values, n (%) 134 (56) 1741 (41) 679 (32) 74 (34) 1075 (48) 3746 (43) 1298 (52)”
Yoshikawa, T., Kishi, T., Shinohara, K., Takesue, K., Shibata, R., Sonoda, N., Inoguchi, T., Sunagawa, K., Tsutsui, H., & Hirooka, Y. (2017) · Hypertension Research · doi:10.1038/hr.2017.14 · Cited by 49
Monami, M., Zannoni, S., Pala, L., Silverii, G. A., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.163 · Cited by 47
Inzucchi, S. E., Khunti, K., FITCHETT, D. H., Wanner, C., Mattheus, M., George, J. T., Ofstad, A. P., & Zinman, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa321 · Cited by 50
Mannucci, E., Nreu, B., Montereggi, C., Ragghianti, B., Gallo, M., Giaccari, A., Monami, M., Candido, R., Pintaudi, B., Targher, G., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.06.002 · Cited by 53
Chadha, M. D., Das, A. K., Deb, P., Gangopadhyay, K. K., Joshi, S., Kesavadev, J., KOVIL, R. R., Kumar, S., Misra, A., & Mohan, V. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01219-x · Cited by 60
“SAVOR TIMI 53 [64] (saxagliptin) TECOS [65] (sitagliptin) CARMELINA [66] (linagliptin)”
Schnell, O., Standl, E., Catrinoiu, D., Itzhak, B., Lalic, N. M., Rahelić, D., Škrha, J., Valensi, P. E., & Ceriello, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0822-4 · Cited by 53
Montilla, S., Marchesini, G., Sammarco, A., Trotta, M. P., Siviero, P. D., Tomino, C., Melchiorri, D., & Pani, L. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.07.014 · Cited by 49
“Higher BMI at baseline was associated with a greater risk of discontinuation on DPP-4Is and a lower risk on exenatide.”
BackgroundInfluentialAoyama, M., Kawase, H., Bando, Y., Monji, A., & Murohara, T. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002081 · Cited by 47
Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
Kawanami, D., Matoba, K., Sango, K., & Utsunomiya, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081223 · Cited by 46
“Three large randomized trials—SAVOR-TIMI 53 [57], Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) [67], and Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study [68]—did not show any significant reductions in the rates of cardiovascular events by DPP-4 inhibi…”
BackgroundResultInfluentialPantalone, K. M., Misra‐Hebert, A. D., Hobbs, T. M., Wells, B. J., Kong, S. X., Chagin, K. M., Dey, T., Milinovich, A., Weng, W., Bauman, J. M., et al. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12613 · Cited by 51
“1 4186 (30) 6551 (30) 3239 (32) 2 2060 (15) 3083 (14) 1287 (13) ≥ 3 2289 (16) 3321 (15) 1089 (11)”
The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)
Prat, L. I., & Tsochatzis, E. A. (2018) · HORMONES · doi:10.1007/s42000-018-0021-9 · Cited by 50
Sharma, A., Ambrosy, A. P., DeVore, A. D., Margulies, K. B., McNulty, S. E., Mentz, R. J., Hernandez, A. F., Michael Felker, G., Cooper, L. B., Lala, A., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12334 · Cited by 45
“59 Hyperglycaemic event 16% (39) 12% (15) 19% (24) 0.”
Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes
Kramer, C. K., Ye, C., Campbell, S., & Retnakaran, R. R. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.05.021 · Cited by 50
Cosentino, F., Ceriello, A., Baeres, F. M. M., Fioretto, P., Garber, A., Stough, W. G., George, J. T., Grant, P. J., Khunti, K., Langkilde, A. M., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy677 · Cited by 44
Stoian, A. P., Sachinidis, A. G., Stoica, R. A., Nikolić, D., Patti, A. M., & Rizvi, A. A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154295 · Cited by 48
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2020.05.004 · Cited by 45
Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109927 · Cited by 48
Diabetes and coronary artery disease: not just a risk factor
Grant, P. J., Cosentino, F., & Marx, N. (2020) · Heart · doi:10.1136/heartjnl-2019-316243 · Cited by 48
“So far, four placebo-controlled CVOTs with DPP-IV inhibitors have been published (SAVOR-TIMI 53 with Saxagliptin, 34 EXAMINE with Alogliptin, 35 TECOS with Sitagliptin 36 and CARMELINA with Linagliptin 37 ), all showing CV safety of these DPP4-inhibitors with respect to 3-point MACE (SAVOR,…”
Angioedema induced by cardiovascular drugs: new players join old friends
Baş, M., Greve, J., Straßen, U., Khosravani, F., Hoffmann, T. K., & Kojda, G. (2015) · Allergy · doi:10.1111/all.12680 · Cited by 50
“Inhibition of DPP IV by gliptins such as saxagliptin has been shown to reduce the levels of fasting blood glucose and glycated hemoglobin (HbA1c) in type 2 diabetes (30).”
Background
Metadata
- Authors
- Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., Cavender, M. A., Udell, J. A., Desai, N. R., Mosenzon, O., McGuire, D. K., Ray, K. K., Leiter, L. A., & Raz, I.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- AstraZeneca (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Hadassah Medical Center (IL)
- St George's, University of London (GB)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1317-1326
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2064130493
- Cited by
- 3,470
- References
- 38
- Citations by year
- 2026: 82 · 2025: 137 · 2024: 129 · 2023: 157 · 2022: 182 · 2021: 233 · 2020: 322 · 2019: 324 · 2018: 365 · 2017: 392 · 2016: 422 · 2015: 337 · 2014: 320 · 2013: 57
- FWCI
- 297.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion)
- Hispana (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Griffith Research Online (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- saxagliptin, type 2 diabetes, DPP-4 inhibitors, cardiovascular safety, cardiovascular outcomes, myocardial infarction, ischemic stroke, cardiovascular mortality, heart failure hospitalization, pancreatitis, non-inferiority, antidiabetic drugs, cardiovascular risk stratification, glycemic control
- MeSH terms
- Adamantane, Aged, Aged, 80 and over, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Dipeptides, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Pancreatitis, Kaplan-Meier Estimate, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.